Sports Medicine

, Volume 38, Issue 12, pp 1065–1079 | Cite as

Keeping Pace with ACE

Are ACE Inhibitors and Angiotensin II Type 1 Receptor Antagonists Potential Doping Agents?
  • Pei Wang
  • Matthew N. Fedoruk
  • Jim L. Rupert
Review Article


In the decade since the angiotensin-converting enzyme (ACE) gene was first proposed to be a ‘human gene for physical performance’, there have been numerous studies examining the effects of ACE genotype on physical performance phenotypes such as aerobic capacity, muscle function, trainability, and athletic status. While the results are variable and sometimes inconsistent, and corroborating phenotypic data limited, carriers of the ACE ‘insertion’ allele (the presence of an alu repeat element in intron 16 of the gene) have been reported to have higher maximum oxygen uptake (V̇O2max), greater response to training, and increased muscle efficiency when compared with individuals carrying the ‘deletion’ allele (absence of the alu repeat). Furthermore, the insertion allele has been reported to be over-represented in elite athletes from a variety of populations representing a number of endurance sports. The mechanism by which the ACE insertion genotype could potentiate physical performance is unknown. The presence of the ACE insertion allele has been associated with lower ACE activity (ACEplasma) in number of studies, suggesting that individuals with an innate tendency to have lower ACE levels respond better to training and are at an advantage in endurance sporting events. This could be due to lower levels of angiotensin II (the vasoconstrictor converted to active form by ACE), higher levels of bradykinin (a vasodilator degraded by ACE) or some combination of the two phenotypes.

Observations that individuals carrying the ACE insertion allele (and presumably lower ACEplasma) have an enhanced response to training or are over-represented amongst elite athletes raises the intriguing question: would individuals with artificially lowered ACEplasma have similar training or performance potential? As there are a number of drugs (i.e. ACE inhibitors and angiotensin II type 1 receptor antagonists [angiotensin receptor blockers — ARBs]) that have the ability to either reduce ACEplasma activity or block the action of angiotensin II, the question is relevant to the study of ergogenic agents and to the efforts to rid sports of ‘doping’. This article discusses the possibility that ACE inhibitors and ARBs, by virtue of their effects on ACE or angiotensin II function, respectively, have performance-enhancing capa. bilities; it also reviews the data on the effects of these medications on V̇O2max, muscle composition and endurance capacity in patient and nonpatient populations. We conclude that, while the direct evidence supporting the hypothesis that ACE-related medications are potential doping agents is not compelling, there are insufficient data on young, athletic populations to exclude the possibility, and there is ample, albeit indirect, support from genetic studies to suggest that they should be. Unfortunately, given the history of drug experimentation in athletes and the rapid appropriation of therapeutic agents into the doping arsenal, this indirect evidence, coupled with the availability of ACE-inhibiting and ACE-receptor blocking medications may be sufficiently tempting to unscrupulous competitors looking for a shortcut to the finish line.


  1. 1.
    Taylor RR, Mamotte CD, Fallon K, et al. Elite athletes and the gene for angiotensin-converting enzyme. J Appl Physiol 1999; 87 (3): 1035–7PubMedGoogle Scholar
  2. 2.
    Woods D, Hickman M, Jamshidi Y, et al. Elite swimmers and the D allele of the ACE I/D polymorphism. HumGenet 2001; 108 (3): 230–2PubMedGoogle Scholar
  3. 3.
    Diet F, Graf C, Mahnke N, et al. ACE and angiotensinogen gene genotypes and left ventricular mass in athletes. Eur JClin Invest 2001; 31 (10): 836–42Google Scholar
  4. 4.
    Scanavini D, Bernardi F, Castoldi E, et al. Increased frequency of the homozygous II ACE genotype in Italian Olympic endurance athletes. Eur J Hum Genet 2002; 10 (10): 576–7PubMedGoogle Scholar
  5. 5.
    Rankinen T, Wolfarth B, Simoneau JA, et al. No association between the angiotensin-converting enzyme IDpolymorphism and elite endurance athlete status. J Appl Physiol 2000; 88 (5): 1571–5PubMedGoogle Scholar
  6. 6.
    Lucia A, Gomez-Gallego F, Chicharro JL, et al. Is there an association between ACE andCKMMpolymorphisms andcycling performance status during 3-week races? Int J Sports Med 2005; 26 (6): 442–7PubMedGoogle Scholar
  7. 7.
    Woods DR, Brull D, Montgomery HE. Endurance and the ACE I/D polymorphism. Sci Prog 2000; 83: 317–36PubMedGoogle Scholar
  8. 8.
    Jones A, Montgomery HE, Woods DR. Human performance: a role for the ACE genotype? Exerc Sport Sci Rev 2002; 30 (4): 184–90PubMedGoogle Scholar
  9. 9.
    Kurdi M, De Mello WC, Booz GW. Working outside the system: an update on the unconventional behavior of therenin-angiotensin system components. Int J Biochem Cell Biol 2005; 37 (7): 1357–67PubMedGoogle Scholar
  10. 10.
    Danser AH, Batenburg WW, van den Meiracker AH, et al. ACE phenotyping as a first step toward personalizedmedicine for ACE inhibitors. Why does ACE genotypingnot predict the therapeutic efficacy of ACE inhibition?Pharmacol Ther 2007; 113 (3): 607–18PubMedGoogle Scholar
  11. 11.
    Cambien F, Alhenc-Gelas F, Herbeth B, et al. Familial resemblance of plasma angiotensin-converting enzymelevel: the Nancy Study. Am J Hum Genet 1988; 43 (5): 774–80PubMedGoogle Scholar
  12. 12.
    Reneland R, Lithell H.Angiotensin-converting enzyme in human skeletal muscle: a simple in vitro assay of activity inneedle biopsy specimens. Scand J Clin Lab Invest 1994; 54(2): 105–11PubMedGoogle Scholar
  13. 13.
    Danser AH. Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 2003; 35 (6): 759–68PubMedGoogle Scholar
  14. 14.
    Van Kats JP, Duncker DJ, Haitsma DB, et al. Angiotensinconverting enzyme inhibition and angiotensin II type 1receptor blockade prevent cardiac remodeling in pigs aftermyocardial infarction: role of tissue angiotensin II. Circulation 2000; 102 (13): 1556–63PubMedGoogle Scholar
  15. 15.
    Montgomery HE, Marshall R, Hemingway H, et al. Human gene for physical performance. Nature 1998; 393: 221–2PubMedGoogle Scholar
  16. 16.
    Rupert JL, Kidd KK, Norman LE, et al. Genetic polymorphisms in the renin-angiotensin system in high-altitudeand low-altitude Native American populations. Ann Hum Genet 2003; 67 (1): 17–25PubMedGoogle Scholar
  17. 17.
    Gesang L, Liu G, Cen W, et al. Angiotensin-converting enzyme gene polymorphism and its association with essentialhypertension in a Tibetan population. HypertensRes 2002; 25 (3): 481–5PubMedGoogle Scholar
  18. 18.
    Cai Q, Liu HJ, Jiang MC, et al. A study of insertion/ delation polymorphism of the angiotensin-convertingenzyme gene in pilots [in Chinese]. Yi Chuan 2002; 24(1): 6–8PubMedGoogle Scholar
  19. 19.
    Gayagay G, Yu B, Hambly B, et al. Elite endurance athletes and the ACE I allele: the role of genes in athletic performance. Hum Genet 1998; 103 (1): 48–50PubMedGoogle Scholar
  20. 20.
    Alvarez R, Terrados N, Ortolano R, et al. Genetic variation in the renin-angiotensin system and athletic performance. Eur J Appl Physiol 2000; 82 (1-2): 117–20PubMedGoogle Scholar
  21. 21.
    Collins M, Xenophontos SL, Cariolou MA, et al. The ACE gene and endurance performance during the South African Ironman Triathlons. Med Sci Sports Exerc 2004; 36 (8): 1314–20PubMedGoogle Scholar
  22. 22.
    Nazarov IB, Woods DR, Montgomery HE, et al. The angiotensin converting enzyme I/D polymorphism in Russianathletes. Eur J Hum Genet 2001; 9 (10): 797–801PubMedGoogle Scholar
  23. 23.
    Scott RA, Moran C, Wilson RH, et al. No association between angiotensin converting enzyme (ACE) genevariation and endurance athlete status in Kenyans. Comp Biochem Physiol A Mol Integr Physiol 2005; 141 (2): 169–75PubMedGoogle Scholar
  24. 24.
    Amir O, Amir R, Yamin C, et al. The ACE deletion allele is associated with Israeli elite endurance athletes. Exp Physiol 2007; 92 (5): 881–6PubMedGoogle Scholar
  25. 25.
    Myerson S, Hemingway H, Budget R, et al. Human angiotensin I-converting enzyme gene and endurance performance.J Appl Physiol 1999; 87 (4): 1313–6PubMedGoogle Scholar
  26. 26.
    Forrester T, McFarlane-Anderson N, Bennett FI, et al. The angiotensin converting enzyme and blood pressure inJamaicans. Am J Hypertens 1997; 10 (5 Pt 1): 519–24PubMedGoogle Scholar
  27. 27.
    Payne JR, Dhamrait SS, Gohlke P, et al. The impact of ACE genotype on serum ACE activity in a blackSouth African male population. Ann Hum Genet 2007; 71 (Pt 1): 1–7PubMedGoogle Scholar
  28. 28.
    Woods DR, Humphries SE, Montgomery HE. The ACE I/D polymorphism and human physical performance. Trends Endocrinol Metab 2000; 11 (10): 416–20PubMedGoogle Scholar
  29. 29.
    Dekany M, Harbula I, Berkes I, et al. The role of insertion allele of angiotensin converting enzyme gene in higherendurance efficiency and some aspects of pathophysiologicaland drug effects. Curr Med Chem 2006; 13 (18): 2119–26PubMedGoogle Scholar
  30. 30.
    Sayed-Tabatabaei FA, Oostra BA, Isaacs A, et al. ACE polymorphisms. Circ Res 2006; 98 (9): 1123–33PubMedGoogle Scholar
  31. 31.
    Montgomery H, Brull D. Gene-environment interactions and the response to exercise. Int J Exp Pathol 2000; 81 (5): 283–7PubMedGoogle Scholar
  32. 32.
    Williams AG, Rayson MP, Jubb M, et al. The ACE gene and muscle performance. Nature 2000; 403 (6770): 614PubMedGoogle Scholar
  33. 33.
    Woods DR, World M, Rayson MP, et al. Endurance enhancement related to the human angiotensin I-convertingenzyme I-D polymorphism is not due to differences in thecardiorespiratory response to training. Eur J Appl Physiol 2002; 86 (3): 240–4PubMedGoogle Scholar
  34. 34.
    Thompson PD, Tsongalis GJ, Ordovas JM, et al. Angiotensin- converting enzyme genotype and adherence toaerobic exercise training. Prev Cardiol 2006; 9 (1): 21–4PubMedGoogle Scholar
  35. 35.
    Folland J, Leach B, Little T, et al. Angiotensin-converting enzyme genotype affects the response of human skeletalmuscle to functional overload. Exp Physiol 2000; 85 (5): 575–9PubMedGoogle Scholar
  36. 36.
    Thomis MA, Huygens W, Heuninckx S, et al. Exploration of myostatin polymorphisms and the angiotensin-convertingenzyme insertion/deletion genotype in responses ofhuman muscle to strength training. Eur J Appl Physiol 2004; 92 (3): 267–74PubMedGoogle Scholar
  37. 37.
    Pescatello LS, Kostek MA, Gordish-Dressman H, et al. ACE ID genotype and the muscle strength and sizeresponse to unilateral resistance training. Med Sci Sports Exerc 2006; 38 (6): 1074–81PubMedGoogle Scholar
  38. 38.
    Sonna LA, Sharp MA, Knapik JJ, et al. Angiotensinconverting enzyme genotype and physical performanceduring US Army basic training. J Appl Physiol 2001; 91 (3): 1355–63PubMedGoogle Scholar
  39. 39.
    Montgomery HE, Clarkson P, Dollery C, et al. Association of angiotensin-converting enzyme gene I/D polymorphismwith change in left ventricular mass in response to physicaltraining. Circulation 1997; 96 (3): 741–7PubMedGoogle Scholar
  40. 40.
    Jasinska A, Krzyzosiak WJ. Repetitive sequences that shape the human transcriptome. FEBS Lett 2004; 567 (1): 136–41PubMedGoogle Scholar
  41. 41.
    Rajeevan H, Osier MV, Cheung KH, et al. ALFRED: the ALelle FREquency Database: update. Nucleic Acids Res 2003; 31 (1): 270–1PubMedGoogle Scholar
  42. 42.
    Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/ deletion in the angiotensin I-converting enzymegene accounting for half the variance of serum enzymelevels. J Clin Invest 1990; 86: 1343–6PubMedGoogle Scholar
  43. 43.
    Danser AH, Schalekamp MA, Bax WA, et al. Angiotensinconverting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation 1995; 92 (6): 1387–8PubMedGoogle Scholar
  44. 44.
    Bloem LJ, Manatunga AK, Pratt JH. Racial difference in the relationship of an angiotensin I-converting enzymegene polymorphism to serum angiotensin I-convertingenzyme activity. Hypertension 1996; 27 (1): 62–6PubMedGoogle Scholar
  45. 45.
    Foy CA, McCormack LJ, Knowler WC, et al. The angiotensin- I converting enzyme (ACE) gene I/D polymorphismand ACE levels in Pima Indians. J Med Genet 1996; 33: 336–7PubMedGoogle Scholar
  46. 46.
    Faure-Delanef L, Baudin B, Beneteau-Burnat B, et al. Plasma concentration, kinetic constants, and gene polymorphismof angiotensin I-converting enzyme in centenarians. Clin Chem 1998; 44 (10): 2083–7PubMedGoogle Scholar
  47. 47.
    Tamura T, Johanning GL, Goldenberg RL, et al. Effect of angiotensin-converting enzyme gene polymorphism onpregnancy outcome, enzyme activity, and zinc concentration.Obstet Gynecol 1996; 88 (4 Pt 1): 497–502PubMedGoogle Scholar
  48. 48.
    Rossi GP, Narkiewicz K, Cesari M, et al. Genetic determinants of plasma ACE and renin activity in young normotensivetwins. J Hypertens 1999; 17 (5): 647–55PubMedGoogle Scholar
  49. 49.
    Sayed-Tabatabaei FA, Schut AF, Hofman A, et al. A study of gene: environment interaction on the gene for angiotensinconverting enzyme — a combined functional andpopulation based approach. J Med Genet 2004; 41 (2): 99–103PubMedGoogle Scholar
  50. 50.
    Williams AG, Day SH, Folland JP, et al. Circulating angiotensin converting enzyme activity is correlated with muscle strength. Med Sci Sports Exerc 2005; 37 (6): 944–8PubMedGoogle Scholar
  51. 51.
    Day SH, Gohlke P, Dhamrait SS, et al. No correlation between circulating ACE activity and V̇O2max or mechanical efficiency in women. Eur J Appl Physiol 2007; 99 (1):11–8Google Scholar
  52. 52.
    Suehiro T, Morita T, Inoue M, et al. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originatingfrom the ACE allele with deletion. Hum Genet 2004;115 (2): 91–6PubMedGoogle Scholar
  53. 53.
    Fedorova L, Fedorov A. Introns in gene evolution. Genetica 2003; 118 (2-3): 123–31PubMedGoogle Scholar
  54. 54.
    Zhu X, Bouzekri N, Southam L, et al. Linkage and association analysis of angiotensin I-converting enzyme(ACE)-gene polymorphisms with ACE concentrationand blood pressure. Am J Hum Genet 2001; 68 (5): 1139–48PubMedGoogle Scholar
  55. 55.
    Keavney B, McKenzie CA, Connell JM, et al. Measured haplotype analysis of the angiotensin-I converting enzymegene. Hum Mol Genet 1998; 71 (11): 1745–51Google Scholar
  56. 56.
    Koehle MS, Wang P, Guenette JA, et al. No association between variants in the ACE and angiotensin II receptor 1genes and acute mountain sickness in Nepalese pilgrims tothe Janai Purnima Festival at 4380 metres. High Alt Med Biol 2006; 7 (4): 281–9PubMedGoogle Scholar
  57. 57.
    Cox R, Bouzekri N, Martin S, et al. Angiotensin-1-converting enzyme (ACE) plasma concentration is influencedby multiple ACE-linked quantitative trait nucleotides. Hum Mol Genet 2002; 11 (23): 2969–77PubMedGoogle Scholar
  58. 58.
    Cam FS, Colakoglu M, Sekuri C, et al. Association between the ACE I/D gene polymorphism and physical performancein a homogeneous non-elite cohort. Can J Appl Physiol 2005; 30 (1): 74–86PubMedGoogle Scholar
  59. 59.
    Kanaide H, Ichiki T, Nishimura J, et al. Cellular mechanism of vasoconstriction induced by angiotensin II: it remainsto be determined. Circ Res 2003; 93 (11): 1015–7PubMedGoogle Scholar
  60. 60.
    Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens 2005; 18 (9Pt 2): 134S–41SPubMedGoogle Scholar
  61. 61.
    Hagberg JM, Ferrell RE, McCole SD, et al..V̇O2max isassociated with ACE genotype in postmenopausal women.J Appl Physiol 1998; 85 (5): 1842–6PubMedGoogle Scholar
  62. 62.
    Roltsch MH, Brown MD, Hand BD, et al. No association between ACE I/D polymorphism and cardiovascular hemodynamicsduring exercise in young women. Int J Sports Med 2005; 26 (8): 638–44PubMedGoogle Scholar
  63. 63.
    Rankinen T, Pérusse L, Gagnon J, et al. Angiotensinconverting enzyme ID polymorphism and fitness phenotypein the HERITAGE Family Study. J Appl Physiol 2000; 88: 1029–35PubMedGoogle Scholar
  64. 64.
    Zhao B, Moochhala SM, Tham S, et al. Relationship between angiotensin-converting enzyme ID polymorphismand.V̇O2max of Chinese males. Life Sci 2003; 73 (20):2625–30PubMedGoogle Scholar
  65. 65.
    Zhang B, Tanaka H, Shono N, et al. The I allele of the angiotensin-converting enzyme gene is associated with anincreased percentage of slow-twitch type I fibers in humanskeletal muscle. Clin Genet 2003; 63 (2): 139–44PubMedGoogle Scholar
  66. 66.
    Williams AG, Dhamrait SS, Wootton PT, et al. Bradykinin receptor gene variant and human physical performance. J Appl Physiol 2004; 96 (3): 938–42PubMedGoogle Scholar
  67. 67.
    ACE Inhibitor Myocardial Infarction Collaborative Group (AIMIC). Indications for ACE inhibitorsin the early treatment of acute myocardial infarction:systematic overview of individual data from 100,000patients in randomized trials. Circulation 1998; 97 (22): 2202–12Google Scholar
  68. 68.
    McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors preventdiabetes and cardiovascular disease. Am J Cardiol 2003; 91 (12A.): 30H–7HPubMedGoogle Scholar
  69. 69.
    Hebert LA, Falkenhain ME, Nahman Jr NS, et al. ACE inhibitor and angiotensin II receptor antagonist therapy indiabetic nephropathy. Am J Nephrol 1999; 19 (1): 1–6PubMedGoogle Scholar
  70. 70.
    Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002; 113 (5): 409–18PubMedGoogle Scholar
  71. 71.
    Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptor- independent antiinflammatory and antiaggregatoryproperties of losartan: role of the active metaboliteEXP3179. Circ Res 2002; 90 (7): 770–6PubMedGoogle Scholar
  72. 72.
    Louch WE, Ferrier GR, Howlett SE. Losartan improves recovery of contraction and inhibits transient inward currentin a cellular model of cardiac ischemia and reperfusion. J Pharmacol Exp Ther 2000; 295 (2): 697–704PubMedGoogle Scholar
  73. 73.
    Opie LH. Angiotensin converting enzyme inhibitors. 3rd ed. Cape Town: University of Cape Town Press, 1999Google Scholar
  74. 74.
    Vescovo G, Dalla Libera L, Serafini F, et al. Improved exercise tolerance after losartan and enalapril in heartfailure: correlation with changes in skeletal musclemyosin heavy chain composition. Circulation 1998; 98 (17): 1742–9PubMedGoogle Scholar
  75. 75.
    Corder CN, Rubler S, Deere LF, et al. Effect of cilazapril on exercise tolerance in congestive heart failure. Pharmacology 1993; 46 (3): 148–54PubMedGoogle Scholar
  76. 76.
    Leon AS, McNally C, Casal DC, et al. Enalapril alone and combined with hydrochlorothiazide in the treatment ofhypertension: effect on treadmill exercise performance. J Cardiac Rehab 1986; 6: 251–6Google Scholar
  77. 77.
    Gordon NF, Myburgh DP, Neutral JM, et al. Comparison of captopril and conventional step I antihypertensive therapy:effects on exercise performance. J Cardiopulm Rehab 1988; 8: 108–15Google Scholar
  78. 78.
    Vanhees L, Fagard R, Lijnen P, et al. Effect of antihypertensive medication on endurance exercise capacityin hypertensive sportsmen. J Hypertens 1991; 9 (11): 1063–8PubMedGoogle Scholar
  79. 79.
    Guazzi M, Palermo P, Pontone G, et al. Synergistic efficacy of enalapril and losartan on exercise performance andoxygen consumption at peak exercise in congestive heartfailure. Am J Cardiol 1999; 84 (9): 1038–43PubMedGoogle Scholar
  80. 80.
    Pascual Figal DA, de la Morena Valenzuela G, Nicolas Ruiz F, et al. Addition of an angiotensin II receptor blockerto maximal dose of ACE inhibitors in heart failure. RevEsp Cardiol 2002; 55 (8): 862–6PubMedGoogle Scholar
  81. 81.
    Munzel T, Kurz S, Drexler H. Are alterations of skeletal muscle ultrastructure in patients with heart failure reversibleunder treatment with ACE-inhibitors [in German]?Herz 1993; 18 Suppl. 1: 400–5Google Scholar
  82. 82.
    Aldigier JC, Huang H, Dalmay F, et al. Angiotensinconverting enzyme inhibition does not suppress plasmaangiotensin II increase during exercise in humans. J CardiovascPharmacol 1993; 21 (2): 289–95PubMedGoogle Scholar
  83. 83.
    Fagard R, Lijnen P, Vanhees L, et al. Hemodynamic response to converting enzyme inhibition at rest and exercisein humans. J Appl Physiol 1982; 53 (3): 576–81PubMedGoogle Scholar
  84. 84.
    Predel HG, Rohden C, Heine O, et al. ACE inhibition and physical exercise: studies on physical work capacity, energymetabolism, and maximum oxygen uptake in well-trained,healthy subjects. J Cardiovasc Pharmacol 1994; 23 Suppl.1: 25–S8Google Scholar
  85. 85.
    Carre F, Handschuh R, Beillot J, et al. Effects of captopril chronic intake on the aerobic performance and musclestrength of normotensive trained subjects. Int J Sports Med 1992; 13 (4): 308–12PubMedGoogle Scholar
  86. 86.
    Sumukadas D, Witham MD, Struthers AD, et al. Effect of perindopril on physical function in elderly people withfunctional impairment: a randomized controlled trial. CMAJ 2007; 177 (8): 867–74PubMedGoogle Scholar
  87. 87.
    Schaufelberger M, Andersson G, Eriksson BO, et al. Skeletal muscle changes in patients with chronic heartfailure before and after treatment with enalapril. Eur Heart J 1996; 17 (11): 1678–85PubMedGoogle Scholar
  88. 88.
    Onder G, Vedova CD, Pahor M. Effects of ACE inhibitors on skeletal muscle. Curr Pharm Des 2006; 12 (16): 2057–64PubMedGoogle Scholar
  89. 89.
    Di Bari M, Van De Poll-Franse LV, Onder G, et al. Antihypertensive medications and differences in muscle mass inolder persons: the Health, Aging and Body Compositionstudy. J Am Geriatr Soc 2004; 52 (6): 961–6PubMedGoogle Scholar
  90. 90.
    Minami N, Mori N, Nagasaka M, et al. Effect of high-salt diet or chronic captopril treatment on exercise capacity innormotensive rats. Clin Exp Pharmacol Physiol 2004; 31 (4): 197–201PubMedGoogle Scholar
  91. 91.
    Minami N, Li Y, Guo Q, et al. Effects of angiotensin-converting enzyme inhibitor and exercise training on exercise capacity and skeletal muscle. J Hypertens 2007; 25 (6): 1241–8PubMedGoogle Scholar
  92. 92.
    Bahi L, Koulmann N, Sanchez H, et al. Does ACE inhibition enhance endurance performance and muscleenergy metabolism in rats? J Appl Physiol 2004; 96 (1): 59–64PubMedGoogle Scholar
  93. 93.
    Rouyer O, Zoll J, Daussin F, et al. Effect of angiotensinconverting enzyme inhibition on skeletal muscle oxidativefunction and exercise capacity in streptozotocin-induceddiabetic rats. Exp Physiol 2007; 92 (6): 1047–56PubMedGoogle Scholar
  94. 94.
    Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensinconvertingenzyme inhibition improves exercise capacity inpatients with severe congestive heart failure. Circulation 1999; 99 (8): 990–2PubMedGoogle Scholar
  95. 95.
    Cooke GA, Williams SG, Marshall P, et al. A mechanistic investigation of ACE inhibitor dose effects on aerobic exercisecapacity in heart failure patients. Eur Heart J 2002;23 (17): 1360–8PubMedGoogle Scholar
  96. 96.
    Williams SG, Cooke GA, Wright DJ, et al. Disparate results of ACE inhibitor dosage on exercise capacity in heartfailure: a reappraisal of vasodilator therapy and study design. Int J Cardiol 2001; 77 (2-3): 239–45PubMedGoogle Scholar
  97. 97.
    Ueda S, Meredith PA, Morton JJ, et al. ACE (I/D) genotype as a predictor of the magnitude and duration of theresponse to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98 (20): 2148–53PubMedGoogle Scholar
  98. 98.
    Nakano Y, Oshima T, Watanabe M, et al. I-converting enzyme gene polymorphism and acute response to captoprilin essential hypertension. Am J Hypertens 1997; 10 (9 Pt 1): 1064–8PubMedGoogle Scholar
  99. 99.
    Taylor JS, Ellis GR. Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure. Am J Cardiovasc Drugs 2002; 2 (6): 389–99PubMedGoogle Scholar
  100. 100.
    Benetos A, Cambien F, Gautier S, et al. Influence of the angiotensin II type 1 receptor gene polymorphism on theeffects of perindopril and nitrendipine on arterial stiffnessin hypertensive individuals. Hypertension 1996; 28 (6): 1081–4PubMedGoogle Scholar
  101. 101.
    Hoogeveen AR. The effect of endurance training on the ventilatory response to exercise in elite cyclists. Eur J ApplPhysiol 2001; 82 (1-2): 45–51Google Scholar
  102. 102.
    Mutton DL, Loy SF, Rogers DM, et al. Effect of run vs combined cycle/run training on.V̇O2max and runningperformance. Med Sci Sports Exerc 1993; 25 (12): 1393–7PubMedGoogle Scholar
  103. 103.
    Connes P, Perrey S, Varray A, et al. Faster oxygen uptake kinetics at the onset of submaximal cycling exercisefollowing 4 weeks recombinant human erythropoietin(r-HuEPO) treatment. Pflugers Arch 2003; 447 (2): 231–8PubMedGoogle Scholar
  104. 104.
    Thomsen JJ, Rentsch RL, Robach P, et al. Prolonged administration of recombinant human erythropoietinincreases submaximal performance more thanmaximal aerobic capacity. Eur J Appl Physiol 2007; 101 (4): 481–6PubMedGoogle Scholar
  105. 105.
    Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimesterexposure to ACE inhibitors. N Engl J Med 2006; 354 (23): 2443–51PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Pei Wang
    • 1
  • Matthew N. Fedoruk
    • 1
  • Jim L. Rupert
    • 1
  1. 1.School of Human KineticsUniversity of British ColumbiaVancouverCanada

Personalised recommendations